Regulatory development can influence pharmaceutical Industry

Pharmaceutical Sector : Dr. Reddy's Laboratories Ltd. Dr. Reddy's Laboratories

came under investor scrutiny after receiving an FDA Form 483 containing two observations following an inspection of its Andhra Pradesh facility. A Form 483 identifies observations made by the US Food and Drug Administration during an inspection; it is not, by itself, a final regulatory determination. Investors should follow the company's response, any corrective actions and subsequent regulatory developments. Pharmaceutical-stock analysis should also include product approvals, generic-drug competition, research expenditure, export exposure and manufacturing quality. Learning takeaway: Regulatory developments can influence pharmaceutical companies, but investors must distinguish inspection observations from final regulatory outcomes.